Westfield Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Westfield Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1B	Sell	4,813,440 -372,256	-7%	-$83.4M	4.62%	2
2025 Q4	$1.11B	Sell	5,185,696 -74,213	-1%	-$15.3M	4.61%	2
2025 Q3	$1.05B	Sell	5,259,909 -191,492	-4%	-$35.7M	4.39%	2
2025 Q2	$941M	Sell	5,451,401 -27,858	-0.5%	-$4.54M	3.95%	2
2025 Q1	$854M	Sell	5,479,259 -48,980	-0.9%	-$7M	4.16%	1
2024 Q4	$761M	Buy	5,528,239 +394,473	+8%	+$51.9M	3.31%	4
2024 Q3	$767M	Buy	5,133,766 +170,942	+3%	+$23.1M	3.46%	4
2024 Q2	$677M	Buy	4,962,824 +887,610	+22%	+$121M	3.33%	4
2024 Q1	$616M	Buy	4,075,214 +44,580	+1%	+$6.36M	3.23%	2
2023 Q4	$508M	Buy	4,030,634 +228,457	+6%	+$22.8M	2.96%	2
2023 Q3	$356M	Buy	3,802,177 +170,465	+5%	+$15.9M	2.43%	4
2023 Q2	$324M	Buy	3,631,712 +485,586	+15%	+$42.3M	2.06%	6
2023 Q1	$337M	Sell	3,146,126 -12,042	-0.4%	-$1.38M	2.38%	3
2022 Q4	$386M	Buy	3,158,168 +247,444	+9%	+$28.7M	2.98%	2
2022 Q3	$301M	Buy	2,910,724 +122,415	+4%	+$11.6M	2.39%	4
2022 Q2	$259M	Buy	2,788,309 +153,282	+6%	+$14.4M	2.04%	5
2022 Q1	$309M	Sell	2,635,027 -5,907	-0.2%	-$684K	1.98%	6
2021 Q4	$355M	Buy	2,640,934 +529,441	+25%	+$78.8M	2.11%	6
2021 Q3	$337M	Buy	2,111,493 +95,566	+5%	+$13.1M	2.03%	6
2021 Q2	$265M	Buy	2,015,927 +148,234	+8%	+$19.8M	1.59%	8
2021 Q1	$241M	Buy	1,867,693 +137,812	+8%	+$20.9M	1.5%	8
2020 Q4	$289M	Sell	1,729,881 -59,893	-3%	-$9.9M	1.71%	7
2020 Q3	$276M	Buy	1,789,774 +351,109	+24%	+$50.5M	1.79%	6
2020 Q2	$213M	Buy	1,438,665 +75,323	+6%	+$10.3M	1.46%	10
2020 Q1	$154M	Buy	1,363,342 +102,586	+8%	+$13.3M	1.35%	12
2019 Q4	$175M	Buy	1,260,756 +136,702	+12%	+$15.2M	1.25%	15
2019 Q3	$108M	Buy	1,124,054 +152,302	+16%	+$17M	0.87%	27
2019 Q2	$112M	Buy	971,752 +285,207	+42%	+$34.1M	0.84%	33
2019 Q1	$80.8M	Buy	686,545 +147,425	+27%	+$12.9M	0.61%	58
2018 Q4	$33.8M	Sell	539,120 -42,614	-7%	-$2.68M	0.29%	109
2018 Q3	$41.2M	Buy	581,734 +157,159	+37%	+$10.8M	0.29%	117
2018 Q2	$28.2M	Buy	+424,575	New	+$27.9M	0.21%	154

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Westfield Capital Management's ASND Position: Q1 2026 in Review

Westfield Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 7.2% in Q1 2026, selling an estimated $83.4M and leaving 4,813,440 shares worth $1.1B. The position accounts for 4.62% of the portfolio, ranked #2.

Westfield Capital Management first reported a position in ASND in Q2 2018 and has held it in 32 quarters since. The position peaked at $1.11B in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Westfield Capital Management held 4,813,440 shares of Ascendis Pharma A/S worth $1.1B as of Q1 2026.
Westfield Capital Management sold 372,256 Ascendis Pharma A/S shares in Q1 2026, an estimated $83.4M.
Ascendis Pharma A/S made up 4.62% of Westfield Capital Management's portfolio in Q1 2026, its #2 holding.
Westfield Capital Management first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 32 quarters since.
Westfield Capital Management's Ascendis Pharma A/S position peaked at $1.11B in Q4 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Westfield Capital Management's 13F filing for Q1 2026, filed 11 May 2026.